Kite Pharma to Present at the 2015 Jefferies Immuno-Oncology Summit in Boston
10 avr. 2015 08h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., April 10, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Announces Publication in Science of Cancer Immunotherapy Articles Authored by Lead Collaborators at the National Cancer Institute and the Netherlands Cancer Institute
06 avr. 2015 08h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., April 6, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Reports Full-Year and Fourth Quarter 2014 Financial Results
26 mars 2015 08h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., March 26, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma to Report Fourth Quarter and Full Year 2014 Financial Results on March 26th, 2015
25 mars 2015 21h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., March 25, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Strengthens Its T Cell Receptor (TCR) Cancer Gene Therapy Platform Through Acquisition of T-Cell Factory B.V. (TCF(TM))
17 mars 2015 08h00 HE
|
Kite Pharma, Inc.
- Kite Pharma EU Established as European Headquarters in Amsterdam, Appointing Ton N. M. Schumacher Ph.D. as its Chief Scientific Officer -
- Kite to Expand Product Pipeline in TCRs for the...
Kite Pharma to Present at the 2015 Barclays Global Healthcare Conference
06 mars 2015 08h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., March 6, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Expands Its Research and Development Collaboration With the National Cancer Institute to Develop a Next Generation of Cancer Immunotherapy Products for Solid Tumors
02 mars 2015 08h00 HE
|
Kite Pharma, Inc.
-Focus on T Cell Response to Tumor-Specific Mutations-
-Expansion of TCR and CAR Product Pipeline-
SANTA MONICA, Calif., Feb. 27, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a...
Kite Pharma to Present at the Cowen and Company 35th Annual Health Care Conference
23 févr. 2015 08h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Establishes Manufacturing Capabilities to Support Development and Commercialization of CAR and TCR Cancer Immunotherapy Products
19 févr. 2015 08h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma to Present at the 17th Annual BIO CEO & Investor Conference
02 févr. 2015 16h30 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...